We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,810.00 | 1,811.00 | 1,812.00 | 1,812.50 | 1,797.00 | 1,805.00 | 4,741,076 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.13 | 74.58B |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it has filed a U.S. regulatory submission for sirukumab in rheumatoid arthritis.
The pharmaceutical giant has submitted a biologics license application to the U.S. Food and Drug Administration by Janssen Biotech, Inc., seeking approval of a subcutaneous formulation of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have failed, or are intolerant to one or more disease-modifying antirheumatic drugs.
Sirukumab is being co-developed for rheumatoid arthritis as part of a collaboration with Janssen Biologics (Ireland), an affiliate of JBI.
A regulatory submission to the European Medicines Agency was announced on Sept. 12. Sirukumab is currently not approved as a treatment for any indication anywhere in the world.
Shares at 1205 GMT down 0.5 pence, or 0.03%, at 1648.5 pence.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
September 23, 2016 08:20 ET (12:20 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
